Literature DB >> 56243

E-type prostaglandins: a new emergency therapy for certain cyanotic congenital heart malformations.

P M Olley, F Coceani, E Bodach.   

Abstract

Prostaglandin E2 (PGE2) has been used to maintain patency of the ductus arteriosus in four neonates with cyanotic congenital heart disease due to obstructive right heart malformations. PGE2 was infused prior to surgery, and in three patients, during surgery until a satisfactory aorto-pulmonary shunt was established. PGE2 produced consistently an immediate and persistent rise in arterial oxygen saturation, which could be ascribed to dilation of the ductus arteriosus. No major side effects occurred, except for pyrexia in two infants. All patients recovered well from surgery. We propose this treatment as preparation for surgery in any infant with congenital heart defects and ductus-dependent pulmonary blood flow. The same treatment may be useful preoperatively in patients with aortic interruption who also depend on continued patency of the ductus for blood supply to the lower half of the body.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 56243     DOI: 10.1161/01.cir.53.4.728

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  50 in total

1.  Intermittent disappearance of a patent ductus arteriosus murmur: report of a case and review of the literature.

Authors:  D V Cokkinos; R D Leachman; R Lufschanowski
Journal:  Tex Heart Inst J       Date:  1982-03

Review 2.  Surgical management of congenital heart defects: current trends.

Authors:  P S Chopra; P S Rao
Journal:  Indian J Pediatr       Date:  1991 Sep-Oct       Impact factor: 1.967

3.  Prostaglandins and the ductus arteriosus.

Authors:  D F Horrobin
Journal:  Can Med Assoc J       Date:  1977-10-08       Impact factor: 8.262

Review 4.  Novel drug targets for ductus arteriosus manipulation: Looking beyond prostaglandins.

Authors:  Elaine L Shelton; Gautam K Singh; Colin G Nichols
Journal:  Semin Perinatol       Date:  2018-05-10       Impact factor: 3.300

5.  Persistent ductus arteriosus: most probably a primary congenital malformation.

Authors:  A C Gittenberger-de Groot
Journal:  Br Heart J       Date:  1977-06

Review 6.  Prostaglandin E1: first stage palliation in neonates with congenital cardiac defects.

Authors:  S C Reddy; A Saxena
Journal:  Indian J Pediatr       Date:  1998 Mar-Apr       Impact factor: 1.967

Review 7.  The future potential of eicosanoids and their inhibitors in paediatric practice.

Authors:  T Shimizu
Journal:  Drugs       Date:  1998-08       Impact factor: 9.546

8.  The prostaglandin challenge. Test to unmask obstructed total anomalous pulmonary venous connections in asplenia syndrome.

Authors:  R M Freedom; P M Olley; F Coceani; R D Rowe
Journal:  Br Heart J       Date:  1978-01

9.  Responses of the post-term arterial duct to oxygen, prostaglandin E2, and the nitric oxide donor, 3-morpholinosydnonimine, in lambs and their clinical implications.

Authors:  S E Abrams; K P Walsh; S J Coker; M J Clarkson
Journal:  Br Heart J       Date:  1995-02

10.  Maintaining patency of the ductus-arteriosus for palliation of cyanotic congenital cardiac malformations. The use of prostaglandin E1 and formaldehyde infiltration of the ductal wall.

Authors:  J Hatem; R M Sade; J K Upshur; A R Hohn
Journal:  Ann Surg       Date:  1980-07       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.